Rankings
▼
Calendar
TSHA
Taysha Gene Therapies, Inc.
$1B
FY 2019 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
$0
Operating Income
-$1M
Net Income
-$1M
EPS (Diluted)
$-0.03
Cash Flow
Operating Cash Flow
$135,000
Free Cash Flow
$135,000
Stock-Based Comp.
$0
Balance Sheet
Total Assets
$15,000
Total Liabilities
$150,000
Stockholders' Equity
-$135,000
Cash & Equivalents
$0
← Q4 2019
All Quarters
TSHA FY 2019 Earnings — Taysha Gene Therapies, Inc. Revenue & Financial Results | Market Cap Arena
